Two patients with the same cancer type can differ in over a thousand biomarkers. The solution is personalized immunotherapy: track each patient's specific signaling pathways and train their immune system to attack the tumor by boosting natural killer cells and dendritic cells.
When we look at two people with the same type and stage of cancer, we look at 1,000+ markers, they have totally different cancers. There's heterogeneity, and it's well published in the data. So how do we handle that? We custom build the medicine for them, tracking their pathway, building their immune system, teaching their body to virtuously kill the cancer. The natural killer cell goes and kills the cancer. There's more release of antigens, more release of damage-associated molecular patterns. There's more release of these peptides. And the new information moves to the dendritic cells, and the natural killer cells now have new information for their cytotoxicity, and they can go to the tumor.
